Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Summit Therapeutics (SMMT) over the last 10 years, with Q2 2025 value amounting to $1.0 million.

  • Summit Therapeutics' Amortizatization of Intangibles fell 3626.17% to $1.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 6807.56%. This contributed to the annual value of $2.6 million for FY2024, which is 3388.77% up from last year.
  • According to the latest figures from Q2 2025, Summit Therapeutics' Amortizatization of Intangibles is $1.0 million, which was down 3626.17% from $3.0 million recorded in Q1 2025.
  • In the past 5 years, Summit Therapeutics' Amortizatization of Intangibles registered a high of $3.0 million during Q1 2025, and its lowest value of -$2.4 million during Q4 2024.
  • For the 5-year period, Summit Therapeutics' Amortizatization of Intangibles averaged around $572133.3, with its median value being $257000.0 (2021).
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first tumbled by 122980.77% in 2024, then surged by 63781.09% in 2025.
  • Over the past 5 years, Summit Therapeutics' Amortizatization of Intangibles (Quarter) stood at $340000.0 in 2021, then plummeted by 113.53% to -$46000.0 in 2022, then skyrocketed by 552.17% to $208000.0 in 2023, then crashed by 1229.81% to -$2.4 million in 2024, then skyrocketed by 143.53% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q2 2025, $3.0 million for Q1 2025, and -$2.4 million during Q4 2024.